Omeros (OMER) closed at $18.44 on October 30, 2026, down 2.7% from the previous close, on volume of 821,953 shares (30-day average 1,224,175).
Data as of October 30, 2026.
30-Oct-2026
Omeros Grants CEO New Performance-Based Stock Options
TipRanks (Fri, 30-Oct 5:39 PM ET)
Globe Newswire (Tue, 27-Oct 6:16 PM ET)
Omeros faces EU setback as CHMP reiterates negative opinion for narsoplimab in TA-TMA
Market Chameleon (Fri, 16-Oct 3:05 AM ET)
Business Wire (Fri, 16-Oct 6:20 AM ET)
Omeros Corporation Reports Second Quarter 2026 Financial Results
Business Wire (Wed, 12-Aug 4:02 PM ET)
Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026
Business Wire (Mon, 10-Aug 8:00 AM ET)
Market Chameleon (Mon, 3-Aug 4:40 AM ET)
CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA
Business Wire (Mon, 3-Aug 8:30 AM ET)
Market Chameleon (Fri, 26-Jun 4:36 AM ET)
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
Omeros trades on the NASDAQ stock market under the symbol OMER.
As of October 30, 2026, OMER stock price declined to $18.44 with 821,953 million shares trading.
OMER has a beta of 2.69, meaning it tends to be more sensitive to market movements. OMER has a correlation of 0.13 to the broad based SPY ETF.
OMER has a market cap of $1.33 billion. This is considered a Small Cap stock.
Last quarter Omeros reported $29 million in Revenue and $.02 earnings per share. This beat revenue expectation by $16 million and exceeded earnings estimates by $.34.
In the last 3 years, OMER traded as high as $21.24 and as low as $1.05.
The top ETF exchange traded funds that OMER belongs to (by Net Assets): VTI, IWM, VXF, BRNY, XPH.
OMER has outperformed the market in the last year with a price return of +140.1% while the SPY ETF gained +11.0%. OMER has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +58.0% and -1.9%, respectively, while the SPY returned +3.9% and -2.1%, respectively.
OMER support price is $18.22 and resistance is $19.68 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OMER shares will trade within this expected range on the day.